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Furthermore, although response to lorazepam did not vary significantly across the different psychiatric diagnoses, patients with acute and transient psychotic disorders did show greater improvement.
A new finding was the positive correlation between psychopathology based on BPRS scores before treatment and the severity of catatonia. However, there was no correlation between BPRS scores before treatment and the scores of catatonia on BFCRS following treatment. This indicated that the severity of psychopathology did not have any predictive value in the therapeutic response of lorazepam in catatonia. Other novel findings not alluded to before in the available literature included the faster onset of action of intravenous lorazepam in comparison to oral lorazepam. There was a significant difference between the oral and parenteral groups after half an hour of treatment. This may be attributed to difference in pharmacokinetics between the two routes of lorazepam administration. However, the treatment response did not differ between the two groups after 96 hours of treatment. Moreover, response of catatonic signs to low dose and high dose lorazepam did not differ significantly in either the oral or the parenteral group.
Although our study is of open-label design, nevertheless it allows a few tentative conclusions. First, schizophrenia along with acute and transient psychotic disorders remain a dominant cause of catatonic syndrome in India, which differs from western studies implicating affective disorders as the main cause (Rosebush et al., 1990; Bush et al.,1996) . Second, an initial dramatic improvement in catatonic symptomatology on parenteral lorazepam has no predictive value in ascertaining future response to it. Third, over a period of four days, there is no significant difference in response of catatonic signs to oral or parenteral lorazepam. Finally, no additional benefit is accrued by giving higher doses of lorazepam in the treatment of catatonic syndrome. 
LETTERS TO

PSYCHIATRIC ILLNESS AND THE LUNAR SYNODIC CYCLE
Sir,
On the basis of the data that they had collected, Parmeshwaran et al.(1999) concluded that a significant relationship exists between phases of the lunar synodic cycle and the development of psychiatric morbidity. From a methodological perspective, I have a reservation about their validity of their conclusions : Parmeshwaran et al.(1999) studied patients at the time of admission and not at the time of onset or exacerbation of symptoms. Since onset or exacerbation of symptoms is likely to precede admission by day to months, all that can be concluded from their data is that there appears to be an association between phases of the moon and the decision to present at psychiatric services. Such an association is very hard to explain on the basis of geomagnetic and other forces.
From a theoretical perspective, I wish to point out that fluctuations in the gravitational field of the moon are very small; this is easily judged from the fact that the tidal effect is merely a few feet in height, on a body of water that is up to-6 miles deep. Therefore, the minor influence of the moon on biological functions is likely to be drowned out by the background noise generated by terrestrial biopsychosocial variables  or  compensated  for  by  neuropsychological and neurochemical  homeostatic mechanisms. Finally, the authors use their full moon data to hypothesize that solar radition influences non-affective psychoses. They state that "the new moon must be obstructing a sufficient number of these charged particles from reaching the earth". This does not make sense because the visibility of the moon depends upon light reflected from the sun and because the new moon and full moon are nocturnal phenomena that occur when the sun is shining on the opposite side of the earth relative to the observer. The issue of the moon blocking solar radiation therefore does not arise.
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